Abstract 5035
Background
Although pancreatic cancer has irregular shape in three-dimensional (3D), when T staging by imaging, only the axial plane is generally used to measure the largest diameter of the mass. We analysed the size of the pancreatic cancer from multi-plane and 3D reconstructed CT images and investigated their clinical usefulness.
Methods
Patients who underwent surgery for pancreatic adenocarcinoma from 2009 to 2016 were included in this study. We measured the largest diameter of pancreatic cancer in axial, coronal, and sagittal planes of CT. In addition, semi-automated segmentation was performed and three-dimensional (3D) maximal diameter and cancer volume were obtained. The obtained data were compared with the actual pathology report and the effect of each value on prognosis was analyzed by receiver operating characteristics (ROC) curves.
Results
A total of 183 patients were analyzed. The maximal pathologic diameter of cancer was 3.4 ± 1.4 cm and median survival was 18.1 months. The maximal diameters measured in axial, coronal, and sagittal planes were 2.9 ± 1.1, 3.2 ± 1.0, and 3.2 ± 0.9, respectively, which were significantly smaller than pathologic data (all p < 0.05 by paired T test). The longest diameter among measured on the 3 planes (3.4 ± 1.1) were not significantly different from that of pathologic report and maximal diameter from 3D image (3.8 ± 1.3) was larger than pathologic diameter. Cancer volume demonstrated the higher area under the ROC curve [0.714, (95% confidence interval: 0.640-0.788)] in predicting early death within 18 months than any measured diameter.
Conclusions
The diameter of pancreatic cancer needs to be measured on all of axial, coronal, and sagittal planes of CT. Cancer volume had a stronger correlation with overall survival than cancer diameter.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Research Foundation of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract